Rimegepant (formerly known as BMS-927711; Nurtec ODT) is a highly potent, selective, orally bioavailable, cometitive calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki value of 0.027 nM.

Ubrogepant (formerly known as MK-1602; MK1602; Ubrelvy) is a novel, potent, orally bioavailable antagonist of calcitonin gene-related peptide receptor (CGRP) approved in 2019 for the acute treatment of migraine with or without aura in adults.

MK-3207 is a novel, potent and orally bioactive CGRP (Calcitonin gene related peptide) receptor antagonist with IC50 and Kiof 0.12 nM and 0.022 nM, it is highly selective versus human AM1, AM2, CTR, and AMY3.

GRA Ex-25 is a novel and potent inhibitor of glucagon receptor with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.

MK-3207 HCl (MK-3207; MK3207), the hydrochloride salt of MK3207, is a novel, potent and orally bioactive CGRP (Calcitonin gene related peptide) receptor antagonist with important biological activity.

Calcitonin salmon is a novel and potent dual-action amylin and calcitonin receptor agonist.